Targeting driver mutations in non-small cell lung cancer
More details
Hide details
Laboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, Faculty of Medicine, University of Patras, 26504 Rio, Greece
Antonia Marazioti   

Laboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, Faculty of Medicine, University of Patras; Basic Biomedical Sciences Research Building, 2nd floor, Room B40, 1 Asklepiou Str., University Campus (Panepistimioupolis), 26504 Rio, Greece
Pneumon 2015;28(2):130–132
The authors received funding for their research in the form of research grants, awards, and scholarships, as well as travel awards from the European Research Council (GTS), the Hellenic Thoracic Society (MV and GTS), the European Respiratory Society (MV, AM, and GTS), as well as the Hellenic Association for Molecular Cancer Research (AM)
Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin 2013;63:11-30.
Zalcman G, Bergot E, Creveuil C, Levallet G, Lechapt E. Integrating biomarkers into clinical trials: methodological issues for a new paradigm in nonsmall cell lung cancer. Curr Opin Oncol 2011;23:106-11.
Carney DN. Lung cancer- time to move on from chemotherapy. New Engl J Med 2002;346:126-28.
Stella GM, Luisetti M, Pozzi E, Comoglio PM. Oncogenes in non-small-cell lung cancer: emerging connections and novel therapeutic dynamics. Lancet Respir Med 2013;1:251-61.
Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-81.
Liu L, Shao X, Gao W, et al. The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a metaanalysis of published data. J Thorac Oncol 2010;5:1922-32.
Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small cell lung cancer. Nat Rev Cancer 2010;10:760-74.
Yamamoto H, Shigematsu H, Nomura M, et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 2008;68:6913-21.
Jin G, Kim MJ, Jeon HS, et al. PTEN mutations and relationship to EGFR, ERBB2, KRAS and TP53 mutations in non-small cell lung cancers. Lung Cancer 2010;69:279-83.
Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561–567.
Massarelli E, Varella-Garcia M, Tang X, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2007;13:2890-96.
Wilhelm SM, Carter C, Tang L, et al. BAY-43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-7109.
Gabrilovich DI. Adenoviral p53 gene therapy for cancer. Expert Opin Biol Ther 2006;6:823-832.
Seo JS, Ju YS, Lee WC, et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res 2012;22:2109-19.
Drake CG, Lipson EJ, Brahmer JR. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol 2014;11:24-37.